Industry news that matters to you.  Learn more

Archives for October 2015

Berg Joins U.K. Prime Minister’s Initiative, Genomics England to Sequence 100,000 Genomes

Berg, a Boston-based biopharmaceutical company at the forefront of precision medicine, today announced it will join an industry collaboration with Genomics England. Formed by U.K. Prime Minister David Cameron, Genomics England is partnering with innovative health companies like Berg to accomplish its mission to sequence 100,000 human genomes and create a new genomic medicine service for the National Health Services (NHS) by 2017. The project focuses on patients with rare diseases and six common cancers.

Quest Diagnostics Introduces Dako’s PD-L1 Companion Diagnostic for KEYTRUDA, Merck’s Anti-PD-1 Therapy for Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx™ immunohistochemistry companion diagnostic.

Hawai’i Pathologists’ Laboratory Launches First-in-Hawaii Tumor DNA Profiling Tests using GenomOncology’s GO Precision Medicine Portfolio

GenomOncology and Hawai’i Pathologists’ Laboratory (HPL) today announced that HPL has launched the state’s first tumor DNA profiling tests based on next generation sequencing (NGS). HPL selected the GenomOncology team and its GO Precision Medicine Portfolio™ to drive their test validation, analysis, interpretation, and reporting processes.